← Compass Therapeutics, Inc. (CMPX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Compass Therapeutics, Inc. (CMPX)
Biological Products, (No Diagnostic Substances) · market cap $211M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-23
Conference
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Compass Therapeutics (CMPX) is a small-cap clinical-stage biotech (35 employees, ~$418M market cap) running three Phase 3 programs: CTX-009 in metastatic colorectal cancer, paclitaxel in biliary tract cancer, and psilocybin in PTSD. The company is pre-revenue with $55.2M cash, a ~9.6-month runway, and an elevated dilution risk flagged at 28%, making near-term capital raises a near-certainty absent a major partnership.
The catalyst path
- 2026-10-23Conferenceimp 5/10
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CTX-009 | Phase 3 | Metastatic Colorectal Cancer |
| Psilocybin | Phase 3 | Post Traumatic Stress Disorder |
Price & technical context
3-month
-60.4%
6-month
-83.4%
12-month
-74.3%
52-wk range
$0.90–$6.69
vs 50-day MA
-54.9%
vs 200-day MA
-75.3%
Realized vol
126.9%
Max drawdown
-86.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CMPX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.